McKesson Corporation
McKesson Reports Fiscal Q2 2025 Results and Raises Full Year Guidance
Summary
McKesson Corporation reported consolidated revenues of $93.7 billion for the second quarter of fiscal 2025, a 21% increase year-over-year. Adjusted earnings per diluted share increased 13% to $7.07. The company also raised its full-year adjusted earnings per diluted share guidance to a range of $32.40 to $33.00 and increased its share repurchase target to $3.2 billion. Detailed financial results and non-GAAP measures are provided in the attached earnings release.
Profitelligence Alerts
Get alerts for MCK
Be first to know when McKesson Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About McKesson Corporation
McKesson Corporation is a leading healthcare services and information technology company. It plays a crucial role in the distribution of pharmaceuticals and medical products. The primary function of McKesson is to ensure the efficient delivery of healthcare products to pharmacies, hospitals, and other medical facilities, ensuring that millions of patients have access to the medications they need. It also provides specialized software and automated solutions that enhance operational efficiency in healthcare sectors. McKesson significantly impacts the pharmaceutical and healthcare industries by offering solutions that streamline supply chains and improve patient care. Its services encompass wholesale drug distribution, healthcare IT systems, and pharmacy management. With operations that extend globally, McKesson is integral to maintaining the integrity and reliability of healthcare supply networks. By handling a substantial portion of the pharmaceutical distribution in North America, McKesson Corporation has a vital market presence, emphasizing its importance in shaping healthcare logistics and innovation. Its efforts contribute to advancing healthcare delivery and responding to the evolving demands of the medical industry.
Official SEC Documents
Advertisement